Table of Contents Table of Contents
Previous Page  734 / 812 Next Page
Information
Show Menu
Previous Page 734 / 812 Next Page
Page Background

S730

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

EV1192

Preventable schizophrenia

C.F. Silvia

, A. Gómez Peinado , P. Cano Ruiz

HNSPS, Psiquiatria, Albacete, Spain

Corresponding author.

Introduction

Schizophrenia is a psychiatric disorder with mul-

tiple causes, including genetic, immune, environmental causes of

various kinds, which all increase the vulnerability and predispo-

sition to the disorder. Among them stand out prenatal infections,

thus being a preventable risk potential factor in our daily clinical

practice.

Objectives

To analyze the relation between prenatal infections

and schizophrenia.

Methods

Review of the subject and recent articles on schizophre-

nia in psychiatric guides and magazines.

Results

After analyzing several studies, it have shown that prena-

tal infections, where the nervous system is not yet fully developed,

may be a risk factor for the development of schizophrenia in adults,

in relationwith genetically predisposed individuals. Infections such

as influenza, especially during the first quarter of gestation; rubella,

toxoplasma and herpes simplex virus-type 2 are related to poten-

tially increase risk of suffer schizophrenia.

Conclusions

Prenatal infections, especially in the first quarter and

the periconceptional period, constitute a risk factor in individuals

with vulnerability to develop schizophrenia. Awareness and pre-

vention is important in the pregnant population of the influence of

these infections on the possible origin of psychotic episodes.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

Further readings

Babulas V, Factor-Litvak P, Goetz R, et al. Prenatal exposure to

maternal genital and reproductive infections and adult schizophre-

nia. Am J Psychiatry 2006;163(5):927–9.

Brown AS, Susser ES. In utero infection and adult schizophrenia.

Ment Retard Dev Disabil Res Rev 2002;8(1):51–7.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2177

EV1193

Medication adherence in

schizophrenia

F. Fatma , I. Baati , S. Omri , R. Sallemi

, J. Masmoudi

Hédi Chaker University Hospital, Psychiatry A, Sfax, Tunisia

Corresponding author.

Introduction

Compliance is a major issue in the treatment of

schizophrenia. Many studies have attempted to identify factors that

influence it.

Objective

To assess treatment adherence in patients with

schizophrenia. To identify factors correlated with poor adherence.

Methods

It was a cross-sectional, descriptive and analyti-

cal study, involving 37 outpatients with DSM-IV diagnosis of

schizophrenia, followed in the psychiatry department at the Hédi

Chaker University Hospital of Sfax (Tunisia). The questionnaire

included socio-demographic, clinical and therapeutic data. We also

used the Medication Adherence Rating Scale “MARS”, the Insight

Scale “IS” and the Stigma Scale (9 items).

Results

The average age was 36.4 years. The majority of patients

was male (68.8%), did not exceed the level of secondary education

(89.2%) and had a low socioeconomic level (84.4%).

Paranoid schizophrenia was the most frequent type of schizophre-

nia (54.1%). Atypical antipsychotic were prescribed in 40.5% of

cases.

Patients were non-adherent to treatment in 56.8% of cases. The fac-

tors correlated with poor adherence were: psychoactive substance

use (

P

= 0.036), sexual dysfunction (

P

= 0.036), complexity of treat-

ment (

P

= 0.036), poor insight according to the subscale “awareness

of the need for treatment” of the IS (

P

= 0.047) and high score on the

subscale “discrimination” of the Stigma Scale (

P

= 0.008).

Conclusion

Tunisian schizophrenic patients have a poor adher-

ence to treatment. Acting on risk factors (such as substance

use, sexual side effects, poor insight and discrimination percep-

tion) would improve patient compliance and management of

schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2178

EV1194

Rehospitalization rate of first episode

and chronic schizophrenia patients

one year after discharge

R. Softic

, E. Becirovic , M. Mirkovic Hajdukov

University Clinical Center Tuzla, Psychiatry Clinic, Tuzla, Bosnia and

Herzegovina

Corresponding author.

Introduction

Relapse rate among patientswith schizophrenia can

determinate outcome of illness. Up to 40% of patients with first psy-

chosis responds well to treatment. Despite this fact relapse rate is

still high, in particular if treatment is discontinuated. Frequent use

of first generation antipsychotics (FGA) in underdeveloped coun-

tries can be one of possible reasons for treatment discontinuation

and consequent relapse.

Aims

To analyse rehospitalisation rate in patients with first and

multiple episodes of schizophrenia, and compare it with medica-

tion choice.

Methods

Retrospective analysis of medical records of patients

with schizophrenia hospitalised in Psychiatry Clinic of University

Clinical Center Tuzla in period from year 2011 to 2013.

Results

During the two-year period, 37 patientswith first episode

of schizophrenia were hospitalised. Second generation antipsy-

chotics (SGA) were used in 40.5%, and first generation in 13.5%, long

acting injectibles - first generation (LAI)were used in8.1%, and com-

bination of FGA’s and SGA’s in 5.4% of cases. In the same period, 121

patientswithmultiple episodes of schizophreniawere hospitalised.

SGAwere used in 21.4%, FGA in 33%, LAI’s in 47.1%, and combination

FGA’s and SGA’s in 35.5% of cases. Relapse rate in the first year after

discharge was 16.2% in group with first psychotic episode, and 33%

in the group with multiple episodes of schizophrenia.

Conclusion

High relapse rate in group withmultiple episodes can

be explained with nonadherence regarding the side effects of too

frequent use of FGA’s.

Keywords

Schizophrenia; Relapse rate; Adherence;

Antipsychotics

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2179

EV1195

Substance abuse in first episode

psychosis: Baseline characteristics and

clinical outcome

A. Toll

, A. M

ané , D. Bergé , V. Pérez-Solà

Hospital del Mar, Institut de Neuropsiquiatria i Addiccions (INAD),

Barcelona, Spain

Corresponding author.

Introduction

There are high rates of substance use disorders

(SUD) amongst first episode psychosis (FEP). SUD have been linked

to better premorbid adjustment, more severe positive and negative

symptoms at presentation and poorer symptomatic and functional

outcome [1]. Moreover, shorter duration of untreated psychosis